Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-25-040196
Filing Date
2025-04-28
Accepted
2025-04-28 16:08:57
Documents
14
Period of Report
2025-06-11

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm2512011-4_def14a.htm   iXBRL DEF 14A 563729
4 GRAPHIC lg_lava-4clr.jpg GRAPHIC 10079
  Complete submission text file 0001104659-25-040196.txt   919490

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA lvtx-20241231.xsd EX-101.SCH 9072
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE lvtx-20241231_lab.xml EX-101.LAB 33989
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2512011-4_def14a_htm.xml XML 1947
Mailing Address YALELAAN 62 UTRECHT P7 3584 CM
Business Address YALELAAN 62 UTRECHT P7 3584 CM 31 6 3000 3035
LAVA Therapeutics NV (Filer) CIK: 0001840748 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40241 | Film No.: 25880378
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)